You can buy or sell CRISPR and other stocks, options, and ETFs commission-free!
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland. The listed name for CRSP is CRISPR Therapeutics AG Common Shares.
52 Week High
52 Week Low
— per share
Expected Feb 10, Pre-Market